Evaluation of the Potential for Drug Interactions with Patiromer in Healthy Volunteers

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 22, Issue 5, 2017, Pages 434-446

  Lesko, Lawrence J ^a   Offman, Elliot ^b   Brew, Christine Taylor ^c   Garza, Dahlia ^c   Benton, Wade ^c   Mayo, Martha R ^c   Romero, Alain ^c   Du Mond, Charles ^c   Weir, Matthew R ^d  

^a UNIVERSITY OF FLORIDA   (United States)

^b CELERION   (United States)

^c Vifor (International) Inc   (Switzerland)

^d UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

absorption; dose separation; drug drug interactions; hyperkalemia; patiromer; potassium binder

Indexed keywords

AMLODIPINE BESYLATE; CINACALCET; CIPROFLOXACIN; CLOPIDOGREL; FUROSEMIDE; LEVOTHYROXINE; LITHIUM CARBONATE; METFORMIN; METOPROLOL TARTRATE; PATIROMER; TRIMETHOPRIM; VERAPAMIL; WARFARIN; POLYMER;

ABDOMINAL DISCOMFORT; ABDOMINAL DISEASE; ABDOMINAL PAIN; ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DRUG ABSORPTION; DRUG DETERMINATION; DRUG SAFETY; DRUG TOLERABILITY; ETHNIC DIFFERENCE; FEMALE; FLATULENCE; GASTROINTESTINAL DISEASE; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; OPEN STUDY; PHARMACOKINETIC ASSAY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE; SUPRAVENTRICULAR TACHYCARDIA; ADOLESCENT; DRUG INTERACTION; MIDDLE AGED; YOUNG ADULT;

ADOLESCENT; ADULT; AREA UNDER CURVE; CROSS-OVER STUDIES; DRUG INTERACTIONS; FEMALE; HEALTHY VOLUNTEERS; HUMANS; MALE; MIDDLE AGED; POLYMERS; YOUNG ADULT;

EID: 85027411197     PISSN: 10742484     EISSN: 19404034     Source Type: Journal    
DOI: 10.1177/1074248417691135     Document Type: Article

References (44)

1. Hayes J, Kalantar-Zadeh K, Lu JL, Turban S, Anderson JE, Kovesdy CP,. Association of hypo- and hyperkalemia with disease progression and mortality in males with chronic kidney disease: the role of race. Nephron Clin Pract. 2012; 120 (1): c8-c16.
2. Sarafidis PA, Blacklock R, Wood E, et al. Prevalence and factors associated with hyperkalemia in predialysis patients followed in a low-clearance clinic. Clin J Am Soc Nephrol. 2012; 7 (8): 1234-1241.
3. Kovesdy CP,. Epidemiology of hyperkalemia: an update. Kidney Int Suppl. 2016; 6 (1): 3-6.
4. Einhorn LM, Zhan M, Hsu VD, et al. The frequency of hyperkalemia and its significance in chronic kidney disease. Arch Intern Med. 2009; 169 (12): 1156-1162.
5. Loutradis C, Tolika P, Skodra A, Avdelidou A, Sarafidis PA,. Prevalence of hyperkalemia in diabetic and non-diabetic patients with chronic kidney disease: a nested case-control study. Am J Nephrol. 2015; 42 (5): 351-360.
6. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY,. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004; 351 (13): 1296-1305.
7. Reardon LC, Macpherson DS,. Hyperkalemia in outpatients using angiotensin-converting enzyme inhibitors. How much should we worry? Arch Intern Med. 1998; 158 (1): 26-32.
8. O'Gara PT, Kushner FG, Ascheim DD, et al.American College of Cardiology Foundation; American Heart Association Task Force on Practice Guidelines; American College of Emergency Physicians; Society for Cardiovascular Angiography and Interventions. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the American College of Emergency Physicians and Society for Cardiovascular Angiography and Interventions. Catheter Cardiovasc Interv. 2013; 82 (1): E1-E27.
9. Ponikowski P, Voors AA, Anker SD, et al.Authors/Task Force Members. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC): developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016; 37 (27): 2129-2200.
10. Palmer BF,. Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system. N Engl J Med. 2004; 351 (6): 585-592.
11. Bozkurt B, Agoston I, Knowlton AA,. Complications of inappropriate use of spironolactone in heart failure: when an old medicine spirals out of new guidelines. J Am Coll Cardiol. 2003; 41 (2): 211-214.
12. Shah KB, Rao K, Sawyer R, Gottlieb SS,. The adequacy of laboratory monitoring in patients treated with spironolactone for congestive heart failure. J Am Coll Cardiol. 2005; 46 (5): 845-849.
13. Epstein M, Reaven NL, Funk SE, McGaughey KJ, Oestreicher N, Knispel J,. Evaluation of the treatment gap between clinical guidelines and the utilization of renin-angiotensin-aldosterone system inhibitors. Am J Manag Care. 2015; 21 (11 suppl): S212-S220.
14. Epstein M, Pitt B,. Recent advances in pharmacological treatments of hyperkalemia: focus on patiromer. Expert Opin Pharmacother. 2016; 17 (10): 1435-1448.
15. Sacks FM, Svetkey LP, Vollmer WM, et al. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. N Engl J Med. 2001; 344 (1): 3-10.
16. Kayexalate® [Sodium Polystyrene Sulfonate]. Prescribing Information. 2014. http://products.sanofi.ca/en/kayexalate.pdf. Accessed May 24, 2016.
17. Harel Z, Gilbert C, Wald R, et al. The effect of combination treatment with aliskiren and blockers of the renin-angiotensin system on hyperkalaemia and acute kidney injury: systematic review and meta-analysis. BMJ. 2012; 344: e42.
18. ® [patiromer] for oral suspension. Full Prescribing Information. 2016. www.veltassa.com/pi.pdf. Accessed January 20, 2017.
19. Li L, Harrison SD, Cope MJ, et al. Mechanism of action and pharmacology of patiromer, a nonabsorbed cross-linked polymer that lowers serum potassium concentration in patients with hyperkalemia. J Cardiovasc Pharmacol Ther. 2016; 21 (5): 456-465.
20. Bakris GL, Pitt B, Weir MR, et al. Effect of patiromer on serum potassium level in patients with hyperkalemia and diabetic kidney disease: The AMETHYST-DN randomized clinical trial. JAMA. 2015; 314 (2): 151-161.
21. Pitt B, Bakris GL, Bushinsky DA, et al. Effect of patiromer on reducing serum potassium and preventing recurrent hyperkalaemia in patients with heart failure and chronic kidney disease on RAAS inhibitors. Eur J Heart Fail. 2015; 17 (10): 1057-1065.
22. Weir MR, Bakris GL, Bushinsky DA, et al. Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors. N Engl J Med. 2015; 372 (3): 211-221.
23. Pitt B, Anker SD, Bushinsky DA, et al.PEARL-HF Investigators. Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial. Eur Heart J. 2011; 32 (7): 820-828.
24. Guidance for Industry. Drug interaction studies-study design, data analysis, implications for dosing, and labeling recommendations. 2012. http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm292362.pdf. Accessed May 24, 2016.
25. Walker JR, Brown K, Rohatagi S, et al. Quantitative structure-property relationships modeling to predict in vitro and in vivo binding of drugs to the bile sequestrant, colesevelam (Welchol). J Clin Pharmacol. 2009; 49 (10): 1185-1195.
26. Synthroid® [levothyroxine sodium tablets, USP]. Product Information. 2012. http://www.rxabbvie.com/pdf/synthroid.pdf/. Accessed June 2, 2016.
27. Anderson GD, Chan LN,. Pharmacokinetic drug interactions with tobacco, cannabinoids and smoking cessation products. Clin Pharmacokinet. 2016; 55 (11): 1353-1368.
28. Fuhr U, Muller-Peltzer H, Kern R, et al. Effects of grapefruit juice and smoking on verapamil concentrations in steady state. Eur J Clin Pharmacol. 2002; 58 (1): 45-53.
29. Gurbel PA, Bliden KP, Logan DK, et al. The influence of smoking status on the pharmacokinetics and pharmacodynamics of clopidogrel and prasugrel: the PARADOX study. J Am Coll Cardiol. 2013; 62 (6): 505-512.
30. Lenzini PA, Grice GR, Milligan PE, et al. Laboratory and clinical outcomes of pharmacogenetic vs. clinical protocols for warfarin initiation in orthopedic patients. J Thromb Haemost. 2008; 6 (10): 1655-1662.
31. Food and Drug Administration. Product-specific recommendations for generic drug development. 2013. http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm075207.htm. Accessed July 27, 2016.
32. Food and Drug Administration. Bioequivalence recommendations for specific products. Draft guidance on metformin hydrochloride. 2008. http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm088672.pdf. Accessed June 2, 2016.
33. Food and Drug Administration. Bioequivalence recommendations for specific products. Draft guidance on levothyroxine sodium. 2014. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM428208.pdf. Accessed June 2, 2016.
34. Glucophage® [metformin hydrochloride] tablets. Product Information. 2009. http://packageinserts.bms.com/pi/pi-glucophage-xr.pdf/. Accessed June 2, 2016.
35. Benedek IH, King SY, Powell RJ, Agra AM, Schary WL, Pieniaszek HJ Jr,. Effect of moricizine on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers. J Clin Pharmacol. 1992; 32 (6): 558-563.
36. Jiang X, Williams KM, Liauw WS, et al. Effect of St John's wort and ginseng on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. Br J Clin Pharmacol. 2004; 57 (5): 592-599.
37. Bushinsky DA, Spiegel DM, Gross C, et al. Effect of patiromer on urinary Ion excretion in healthy adults. Clin J Am Soc Nephrol. 2016; 11 (10): 1769-1776.
38. Rowland M, Tozer TN,. Clinical Pharmacokinetics and Pharmacodynamics. Concepts and Applications. 4th ed. Philadelphia, PA: Lippincott Williams & Wilkens; 1995.
39. Radandt JM, Marchbanks CR, Dudley MN,. Interactions of fluoroquinolones with other drugs: mechanisms, variability, clinical significance, and management. Clin Infect Dis. 1992; 14 (1): 272-284.
40. Sahai J, Gallicano K, Oliveras L, Khaliq S, Hawley-Foss N, Garber G,. Cations in the didanosine tablet reduce ciprofloxacin bioavailability. Clin Pharmacol Ther. 1993; 53 (3): 292-297.
41. Stass H, Kubitza D,. Profile of moxifloxacin drug interactions. Clin Infect Dis. 2001; 32 (suppl 1): S47-S50.
42. Cipro® [ciprofloxacin hydrochloride] tablets, Cipro® [ciprofloxacin] 5% and 10% Oral Suspension. Product Information. 2000. https://www.dartmouth.edu/a1/4genchem/0102/spring/6winn/pdfs/ciprotab.pdf. Accessed June 14, 2016.
43. U.S. Department of Agriculture and U.S. Department of Health and Human Services. Dietary Guidelines for Americans, 2010. 7th ed. Washington, DC: U.S. Government Printing Office; 2010.
44. Camilleri M,. Drug-resin drug interactions in patients with delayed gastric emptying: what is optimal time window for drug administration? Neurogastroenterol Motil. 2016; 28 (8): 1268-1271.